[1]张倩韬,侯敏娜,彭修娟,等.基于整合药理学的经典名方当归补血汤防治糖尿病的作用机制研究[J].中国药理学通报,2019,(09):1314-1319.[doi:10.3969/j.issn.1001-1978.2019.09.024]
 ZHANG Qian-tao,HOU Min-na,PENG Xiu-juan,et al.The predictive analysis of action mechanism for classic TCM excellent prescriptions of Danggui Buxue decoction on diabetes with TCMIP[J].Chinese Pharmacological Bulletin,2019,(09):1314-1319.[doi:10.3969/j.issn.1001-1978.2019.09.024]
点击复制

基于整合药理学的经典名方当归补血汤防治糖尿病的作用机制研究()
分享到:

《中国药理学通报》[ISSN:/CN:]

卷:
期数:
2019年09期
页码:
1314-1319
栏目:
网络药理学
出版日期:
2019-09-09

文章信息/Info

Title:
The predictive analysis of action mechanism for classic TCM excellent prescriptions of Danggui Buxue decoction on diabetes with TCMIP
文章编号:
1001-1978(2019)09-1314-06
作者:
张倩韬1侯敏娜1彭修娟2杜 蓓1蔡 洁1刘 峰23
陕西国际商贸学院 1.医药学院、2.中药研究院,陕西 西安 712046; 3.陕西步长制药有限公司,陕西 西安 710075
Author(s):
ZHANG Qian-tao1 HOU Min-na1 PENG Xiu-juan2 DU Bei1 CAI Jie1 LIU Feng23
1.Medical College, 2.Academy of Chinese Materia Medica, Shaanxi Institute of International Trade & Commerce, Xi'an 712046, China; 3.Shaanxi Buchang Pharmaceutical Company Ltd, Xi'an 710075, China
关键词:
经典名方 当归补血汤 糖尿病 作用机制 药效物质基础 精氨酸加压素受体
Keywords:
classic TCM excellent prescriptions Danggui Buxue decoction diabetes mellitus mechanism pharmacodynamic material basis arginine vasopressin receptor
分类号:
R284.1; R289.5; R392.11; R394.3; R587.102.2; R587.105.31
DOI:
10.3969/j.issn.1001-1978.2019.09.024
文献标志码:
A
摘要:
目的 探究经典名方当归补血汤防治糖尿病(DM)的药效物质基础和作用机制,以期为DM的中药防治提供更多选择。方法 借助中药整合药理学平台(TCMIP),预测分析当归补血汤的作用机制和药效物质基础。结果 当归补血汤中的50个“黄芪-当归”成分,通过直接或间接作用于60个关键药靶,这些药靶作用于神经-内分泌系统、细胞间连接、激素信号通路、心血管循环系统等30条主要调控通路,来纠正DM及其并发症的疾病失衡网络。黄芪中参与DM防治的主要为黄芪皂苷类、黄芪苷类、黄酮类等; 当归中参与DM防治的主要为阿魏酸等有机酸、β-甜没药烯等油性成分、豆甾醇-β-D-葡萄糖苷、伞形花内酯、东莨菪素等。结论 当归补血汤中的50个“黄芪-当归”成分,可能是通过精氨酸加压素受体(AVPR)的3个亚型AVPR1A、AVPR1B和AVPR2相关受体信号通路,来发挥防治DM的作用,且黄芪为关键成分。
Abstract:
Aim To explore the pharmacodynamic material basis and mechanism of the classic TCM excellent prescriptions(cTCMep)Danggui Buxue decoction, so as to provide more choices for the prevention and treatment of diabetes mellitus(DM).Methods With the integrative pharmacology of traditional Chinese medicine(TCMIP), we predicted the pharmacodynamic material basis and mechanisms of the cTCMep Danggui Buxue decoction for treatment of DM.Results The 50 “Astragalus-Angelica” components in the cTCMep Danggui Buxue decoction directly or indirectly acted on 60 key drug targets.These drug targets restored the disease imbalance network of DM and its complications by acting on 30 major regulatory pathways such as nervous-endocrine system, gap junction, hormone signaling pathways, and cardiovascular circulatory system.The main components of Astragalus membranaceus involved in the prevention and treatment of DM were astragalosides, astragalosides and alavonoids.The main components involved in the prevention and treatment of DM in Angelica sinensis were organic acids such as ferulic acid, oil components such as β-sweet myrrh, stigmasterol-β-D-glucoside, smbelliferol and scopolamine.Conclusions The 50 “Astragalus-Angelica” components in the cTCMep Danggui Buxue decoction may play a role in preventing and treating DM through the AVPR1A, AVPR1B and AVPR2(AVPR: arginine vasopressin receptor, three subtypes), of which Astragalus membranaceu is the key component.

参考文献/References:

[1] 李 冀.方剂学[M].第2版.北京: 高等教育出版社, 2014, 113.
[1] Li J.Formulas of Chinese Medicine [M].The Second Edition.Beijing: Higher Education Press, 2014, 113.
[2] 王丽茹.中医药治疗糖尿病消渴症的研究进展[J].中国处方药, 2016, 14(1): 13-4.
[2] Wang L R.A review on treating diabetes in TCM[J].J Chin Preserip Drug, 2016, 14(1):13-4.
[3] 赵晓梅.黄芪当归合剂治疗糖尿病患者的临床疗效[J].中国医药指南, 2017, 15(9): 170-1.
[3] Zhao X M.Clinical effect of Huangqi Danggui mixture on diabetes patients[J].Guide Chin Med, 2017, 15(9): 170-1.
[4] 赵学兰, 林松娟, 张琳琳, 等.黄芪当归合剂治疗糖尿病肾病的临床观察[J].中成药, 2007, 29(5): 641-4.
[4] Zhao X L, Lin S J, Zhang L L, et al.Clinical observation on treatment of diabetic nephropathy with Huangqi Danggui mixture [J].Chin Tradit Patent Med, 2007, 29(5): 641-4.
[5] 中华医学会糖尿病学分会.中国2型糖尿病防治指南[J].中国糖尿病杂志, 2018, 10(1): 4-67.
[5] Chinese Diabetes Society.Guidelines for the prevention and control of type 2 diabetes in china(2017 edition)[J].Chin J Diabetes, 2018, 10(1): 4-67.
[6] 许海玉, 杨洪军.整合药理学:中药现代研究新模式[J].中国中药杂志, 2014, 39(3):357-62.
[6] Xu H Y, Yang H J.Integrative pharmacology: new paradigm of modernization of Chinese medicine[J].Chin J Chin Mater Med, 2014, 39(3): 357-62.
[7] 宋开梅, 赵连友.精氨酸加压素受体及其拮抗剂[J].中国高血压杂志, 1994, 2(S1): 43-7.
[7] Song K M, Zhao L Y.Arginine vasopressin receptors and antagonists[J].Chin J Hypertension, 1994, 2(S1): 43-7.
[8] Ying W, Li H J, Yu Z X, et al.Mutation analysis of AVPR2 and AQP2 gene in Chinese patients with congenital nephrogenic diabetes insipidus[J].Chem Res Chin Univ, 2008, 24(3): 312-5.
[9] 刘 涛, 李 晶, 鲍翠玉.线粒体损伤与糖尿病心肌病发病关系的研究进展[J].中国药理学通报, 2018, 34(4): 456-8.
[9] Liu T, Li J, Bao C Y.Advances on treatment of allergic disease by isoflavonic phytoestrogens[J].Chin Pharmacol Bull, 2018, 34(4): 456-8.
[10] 莫与琳, 杨亚军, 崔 燎.TXNIP介导的氧化应激在疾病中的作用机制[J].中国药理学通报, 2018, 34(1): 16-9.
[10] Mo Y L, Yang Y J, Cui L.Action and mechanism of oxidative stress mediated by TXNIP in diseases[J].Chin Pharmacol Bull, 2018, 34(1): 16-9.
[11] 景 琪, 吴国泰, 杜丽东, 等.当归黄芪醇提物对糖尿病胃轻瘫模型大鼠的治疗作用[J].中药材, 2014, 37(8): 1415-20.
[11] Jing Q, Wu G T, Du L D, et al.Therapeutic effects of ethanol extracts of Angelica sinensis and Astragalus mongholicus in diabetic gastroparesis rats[J].J Chin Med Mater, 2014, 37(8): 1415-20.
[12] 阴永辉.黄芪甲苷与阿魏酸抑制NF-κB信号途径干预糖尿病大鼠大血管病变的作用及机制[D].济南:山东中医药大学, 2014.
[12] Yin Y H.On the role and mechanism of the intervention on diabetic rats macroangiopathy by inhibition of NF-κB signal pathway by astragaloside and ferulic acid[D].Ji'nan: Shandong Traditinal Chinese Medicinal University, 2014.
[13] 张莹雯, 谢 丹.当归补血汤对糖尿病大鼠肾组织的保护作用[J].中成药, 2005, 27(1):79-82.
[13] Zhang Y W, Xie D.Protective effect of Danggui Buxue decoction on the kidney of diabetis rats[J].Chin Tradit Patent Med, 2005, 27(1): 79-82.
[14] 周 肖.当归补血方穴位敷贴对气虚血瘀型糖尿病周围神经病变患者肢体症状的干预研究[D].福州: 福建中医药大学, 2015.
[14] Zhou X.The clinical intervention study of point application with Danggui Buxue prescription on patients with diabetic peripheral neuropathy of qi deficiency and blood stasis type[D].Fuzhou: Fujian University of Traditional Chinese Medicine, 2015.
[15] 郭艺娟.益气养血通络法干预糖尿病视网膜病变的临床与实验研究[D].北京: 中国中医科学院, 2012.
[15] Guo Y J.Clinical and experimental study of nourishing qi, blood and collaterals treatment in diabetic retinopathy[D].Beijing: China Academy of Chinese Medical Sciences, 2012.

备注/Memo

备注/Memo:
收稿日期:2019-05-18,修回日期:2019-06-10
基金项目:国家科技部“重大新药创制”科技重大专项(No 2018ZX09721005-009-013); 生物医药创新制药技术研究院士专家工作站资助项目(陕科协发[2017]事企字15号); 陕西国际商贸学院中药质量标志物创新团队项目(No:SSY18TD02)
作者简介:张倩韬(1984-),女,硕士,讲师,研究方向:药物动力学,E-mail: zqt0526@163.com;
刘 峰(1970-),男,博士,教授,硕士生导师,研究方向:中药经典名方开发,通讯作者,E-mail: liufeng1720@163.com
更新日期/Last Update: 2019-08-14